CTRI/2022/12/048337进行中（未招募）4 期
A 24-week multicenter, open-label, single-arm study to evaluate safety in patients with type 2 diabetes mellitus in India treated with dulaglutide
Eli Lilly and Company India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1. Are 18 years of age or older and an Indian resident.
- •2. Have been diagnosed with T2D for at least 1 year and are being currently treated with oral antidiabetic medicines and/or insulins that are allowed in the study.
- •3. HbA1c value is = 7.5 % and = 11.5 % at Visit 1.
排除标准
- •1. Have been diagnosed with any type of diabetes other than T2D.
- •2. Have any kidney, liver, gastrointestinal, or pancreatic diseases that are not allowed in the study.
- •3. Have certain cancers that are not allowed in the study.
- •4. Have been treated with certain medicines that are not allowed in the study within 3 months before screening.
- •5. Have a known hypersensitivity or allergy to the study medicine or its inactive constituents.
- •6. Are overweight and are a candidate for certain surgeries that are not allowed in the study.
- •7. Are a woman who can get pregnant and are not willing to use an appropriate birth control method during the study.
- •8. Are a woman who is pregnant or breastfeeding.
研究者
相似试验
进行中（未招募）
4 期
Study to investigate the safety of ixekizumab in participants aged =18 years with moderate-to-severe plaque psoriasis and/or active psoriatic arthritis in IndiaCTRI/2023/06/053776Eli Lilly and Company India Pvt Ltd
进行中（未招募）
1 期
A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosisEUCTR2010-022066-28-DEovartis Pharma GmbH445
进行中（未招募）
1 期
A 52-week open-label, single-arm, multi-center study to evaluate the long term safety of pimecrolimus 1% cream intermittent treatment of seborrhoeic dermatitis in patients 12 years of age and olderEUCTR2006-000336-28-DKovartis Pharma Services AG36
进行中（未招募）
1 期
Study of brolucizumab in adult patients with suboptimal anatomically controlled neovascular age-related macular degenerationeovascular age-related macular degenerationMedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2019-004145-33-FRovartis Pharma S.A.S362
已完成
4 期
To Evaluate The Efficacy And Safety Of Nimulid Strong Gel in Subject suffering From Pain Associated With Recent Muscle or Joint Injuries.CTRI/2022/11/047591Mankind Pharma Limited60